Safety and efficacy of post-haematopoietic cell transplantation maintenance therapy with blinatumomab for relapsed/refractory CD19-positive B-cell acute lymphoblastic leukaemia: protocol for a phase I–II, multicentre, non-blinded, non-controlled trial (JPLSG SCT-ALL-BLIN21)

Safety and efficacy of post-haematopoietic cell transplantation maintenance therapy with blinatumomab for relapsed/refractory CD19-positive B-cell acute lymphoblastic leukaemia: protocol for a phase I–II, multicentre, non-blinded, non-controlled trial (JPLSG SCT-ALL-BLIN21)

Introduction Relapsed and refractory B-cell acute lymphoblastic leukaemia (R/R-B-ALL) is linked to a significant relapse rate after allogeneic haematopoietic cell transplantation (allo-HCT) in children, adolescents and young adults (CAYA). No standard treatment has been established to prevent relaps...

Full description

Bibliographic Details
Main Authors: Yoshiyuki Takahashi, Hisashi Noma, Akiko Saito, Keizo Horibe, Hirotoshi Sakaguchi, Katsustugu Umeda, Itaru Kato, Kimiyoshi Sakaguchi, Hidefumi Hiramatsu, Hiroyuki Ishida, Hiromasa Yabe, Hiroaki Goto, Yuta Kawahara, Yuka Iijima Yamashita, Masashi Sanada, Takao Deguchi, Takashi Taga, Souichi Adachi
Format: Article
Language:English
Published: BMJ Publishing Group 2023-04-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/13/4/e070051.full

Internet

https://bmjopen.bmj.com/content/13/4/e070051.full

Similar Items